Skip to main
ACXP

ACXP Stock Forecast & Price Target

ACXP Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Acurx Pharmaceuticals Inc is well-positioned for growth due to positive feedback from both the FDA and EMA regarding its antibiotic candidate, ibezapolstat (IBZ), ahead of the critical Phase 3 trial in adult populations. The company has also demonstrated encouraging antimicrobial activity coupled with a favorable safety profile for IBZ, further enhancing its potential marketability. Additionally, the recent positive opinion from the Pediatric Committee of the EMA on the company's Pediatric Investigation Plan for IBZ indicates broader applicability and regulatory support for the drug's use in children, strengthening the overall outlook for Acurx Pharmaceuticals.

Bears say

Acurx Pharmaceuticals Inc. faces significant challenges due to its clinical stage status, which inherently carries high development risks and uncertainty surrounding successful regulatory approval for its antibiotic candidates. The company is operating in a highly competitive biopharmaceutical sector, where the reliance on government and health organizations for prioritizing its target infections may not guarantee market adoption or profitability. Additionally, the financial metrics are concerning, as the company's limited revenue generation combined with high operational costs and reliance on funding may impede its ability to sustain long-term growth and stability.

ACXP has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Acurx Pharmaceuticals LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Acurx Pharmaceuticals LLC (ACXP) Forecast

Analysts have given ACXP a Strong Buy based on their latest research and market trends.

According to 1 analysts, ACXP has a Strong Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Acurx Pharmaceuticals LLC (ACXP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.